Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
59.62
+0.99 (1.69%)
At close: Aug 18, 2026, 4:00 PM EDT
59.60
-0.02 (-0.04%)
After-hours: Aug 18, 2026, 7:44 PM EDT
Ionis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 874.09 | 943.71 | 705.14 | 787.65 | 587.37 | 810.46 | |
Revenue Growth | -7.41% | 33.83% | -10.47% | 34.10% | -27.53% | 11.13% |
Cost of Revenue | 934.7 | 931.53 | 912.75 | 908.76 | 847.26 | 654.3 |
Gross Profit | -60.6 | 12.18 | -207.61 | -121.11 | -259.9 | 156.16 |
Selling, General & Admin | 533.75 | 393.87 | 267.47 | 232.62 | 150.3 | 186.35 |
Operating Expenses | 533.75 | 393.87 | 267.47 | 232.62 | 150.3 | 186.35 |
Operating Income | -594.35 | -381.68 | -475.08 | -353.73 | -410.19 | -30.19 |
Interest Expense | -89.47 | -90.54 | -90.45 | -81.46 | -8.12 | -9.35 |
Interest & Investment Income | 94.12 | 97.77 | 107.02 | 89.04 | 25.33 | 10.04 |
Other Non Operating Income (Expenses) | 0.95 | 0.99 | 1.33 | 0.71 | -7.27 | -1.13 |
EBT Excluding Unusual Items | -588.76 | -373.48 | -457.18 | -345.44 | -400.26 | -30.62 |
Gain (Loss) on Sale of Investments | 43.1 | 10.22 | -2.89 | -1.91 | -7.33 | 10.1 |
Gain (Loss) on Sale of Assets | - | - | - | - | 149.6 | - |
Other Unusual Items | -16.34 | -16.34 | - | 13.39 | - | -8.63 |
Pretax Income | -562 | -379.6 | -460.07 | -333.97 | -257.99 | -29.15 |
Income Tax Expense | 3.17 | 1.79 | -6.17 | 32.32 | 11.74 | -0.55 |
Earnings From Continuing Operations | -565.17 | -381.39 | -453.9 | -366.29 | -269.72 | -28.6 |
Net Income | -565.17 | -381.39 | -453.9 | -366.29 | -269.72 | -28.6 |
Net Income to Common | -565.17 | -381.39 | -453.9 | -366.29 | -269.72 | -28.6 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 163 | 160 | 150 | 143 | 142 | 141 |
Shares Outstanding (Diluted) | 163 | 160 | 150 | 143 | 142 | 141 |
Shares Change | 4.49% | 7.02% | 4.42% | 0.95% | 0.59% | 1.01% |
EPS (Basic) | -3.46 | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 |
EPS (Diluted) | -3.46 | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -560.84 | -320.03 | -546.23 | -331.32 | -290.09 | 18.84 |
Free Cash Flow Per Share | -3.44 | -2.00 | -3.65 | -2.31 | -2.04 | 0.13 |
Gross Margin | -6.93% | 1.29% | -29.44% | -15.38% | -44.25% | 19.27% |
Operating Margin | -68.00% | -40.45% | -67.37% | -44.91% | -69.84% | -3.72% |
Profit Margin | -64.66% | -40.41% | -64.37% | -46.50% | -45.92% | -3.53% |
Free Cash Flow Margin | -64.16% | -33.91% | -77.46% | -42.06% | -49.39% | 2.33% |
EBITDA | -579.49 | -369.24 | -463.13 | -340.88 | -393.45 | -12.35 |
EBITDA Margin | -66.30% | -39.13% | -65.68% | -43.28% | -66.98% | -1.52% |
D&A For EBITDA | 14.87 | 12.45 | 11.95 | 12.85 | 16.74 | 17.84 |
EBIT | -594.35 | -381.68 | -475.08 | -353.73 | -410.19 | -30.19 |
EBIT Margin | -68.00% | -40.45% | -67.37% | -44.91% | -69.84% | -3.72% |
Revenue as Reported | 874.09 | 943.71 | 705.14 | 787.65 | 587.37 | 810.46 |